OTCMKTS:GNWSFGeneNews Stock Price, Forecast & News

$0.07

0.00 (0.00 %)

(As of 05/25/2020 04:00 PM ET)

Add

Compare

Today's Range

$0.07

Now: $0.07▼

$0.07

50-Day Range

$0.04

MA: $0.07▼

$0.10

52-Week Range

$0.02

Now: $0.07▼

$0.15

Volume25,400 shs

Average Volume39,742 shs

Market Capitalization$22.40 million

P/E RatioN/A

Dividend YieldN/A

Beta3.33

GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for GeneNews.

2.6 Community Rank

Outperform Votes
GeneNews has received 71 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
GeneNews has received 64 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
GeneNews has received 52.59% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about GeneNews and other stocks. Vote “Outperform” if you believe GNWSF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNWSF will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
GeneNews does not currently pay a dividend.
Dividend Growth
GeneNews does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GeneNews insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Overall Beat the Market Rank^™

0.52 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Diagnostic substances

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:GNWSF

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.genenews.com

Phone905-209-2030

Debt

Debt-to-Equity RatioN/A

Current Ratio0.19

Quick Ratio0.14

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$190,000.00

Price / Sales117.89

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.03) per share

Price / Book-2.27

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-3,940,000.00

Net Margins-2,760.90%

Return on EquityN/A

Return on Assets-116.47%

Miscellaneous

Employees16

Outstanding Shares329,390,000

Market Cap$22.40 million

Next Earnings Date5/27/2020 (Estimated)

OptionableNot Optionable

Receive GNWSF News and Ratings via Email

Sign-up to receive the latest news and ratings for GNWSF and its competitors with MarketBeat's FREE daily newsletter.

GeneNews (OTCMKTS:GNWSF) Frequently Asked Questions

How has GeneNews' stock been impacted by COVID-19 (Coronavirus)?

GeneNews' stock was trading at $0.0266 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GNWSF stock has increased by 155.6% and is now trading at $0.0680. View which stocks have been most impacted by Coronavirus.

When is GeneNews' next earnings date?

GeneNews is scheduled to release its next quarterly earnings announcement on Wednesday, May 27th 2020. View our earnings forecast for GeneNews.

Has GeneNews been receiving favorable news coverage?

News articles about GNWSF stock have trended somewhat positive recently, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GeneNews earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the near term. View the latest news aboutGeneNews.

Who are some of GeneNews' key competitors?

Some companies that are related to GeneNews include Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Trinity Biotech (TRIB), ImmuCell (ICCC), Achieve Life Sciences (ACHV), Akers Biosciences (AKER), Arca Biopharma (ABIO), BG Medicine (BGMD), Fluoropharma Medical (FPMI) and Response Genetics (RGDXQ). View all competitors.

Who are GeneNews' key executives?

GeneNews' management team includes the following people:

Mr. James R. Howard-Tripp, Exec. Chairman & CEO
Ms. Joanna M. Halsey Esq., Gen. Counsel, Chief Compliance Officer & HR Director of IDL
Prof. Choong-Chin Liew Ph.D., Co-Founder
Mr. Warren Whitehead, Chief Accountant (Age 67)
Mr. David Suria, Sr. Scientist

What is GeneNews' stock symbol?

GeneNews trades on the OTCMKTS under the ticker symbol "GNWSF."

How do I buy shares of GeneNews?

Shares of GNWSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GeneNews' stock price today?

One share of GNWSF stock can currently be purchased for approximately $0.07.

How big of a company is GeneNews?

GeneNews has a market capitalization of $22.40 million and generates $190,000.00 in revenue each year. GeneNews employs 16 workers across the globe.

What is GeneNews' official website?

The official website for GeneNews is www.genenews.com.

How can I contact GeneNews?

GeneNews' mailing address is 70 East Beaver Creek Road Unit 30, Richmond Hill A6, L4B 3B2. The company can be reached via phone at 905-209-2030 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff